![2025 PSMA conference](/sites/cancer.ucsf.edu/files/styles/sf_landscape_16x9/public/images/article/psma-2025.jpg?h=7bb3fe82&itok=DWRiZnf6 "Julian Hong, MD, presents "Who Benefits from Oligometastasis Directed Therapy?" at the 2025 PSMA & Beyond Conference held at UCLA.")
Julian Hong, MD, presents "Who Benefits from Oligometastasis Directed Therapy?" at the 2025 PSMA & Beyond Conference held at UCLA.
In late March, the third PSMA & Beyond Conference, co-hosted by the University of California, Los Angeles (UCLA) and the University of California, San Francisco (UCSF), with support from the Prostate Cancer Foundation (PCF), was held in Los Angeles. This year the conference focused on the current and future use of PET imaging and radionuclide therapy, including presentations, panel discussions, and exhibits from invited speakers and stakeholders.
Social Media and Video Highlights
Dr. Chu highlights the exciting progress at UCSF utilizing PSMA targeting of prostate cancer in the perioperative period, including intraoperative imaging, post-operative staging, and an upcoming neoadjuvant clinical trial using radioligand therapy. www.guoncologynow.com/post/role-of...
— UCSF Department of Urology (@ucsfurology.bsky.social) April 10, 2025 at 1:34 PM
[image or embed]
@DrMHofman presents at 2025 PSMA & Beyond Conference @UCLA @UCSF @PCFnews ... Impressive attendance!
— ProsTIC (@pros_tic) March 28, 2025
Thanks to organisers:@thomashopemd @CalaisJeremie @CzerninJohannes @urotoday
Don't miss our next webinar: https://t.co/zABXXv5CYP pic.twitter.com/RaMu26TgS3
Whole-body PSMA quantitative parameters: Why are we not using whole-body PSMA PET parameters in the real world? Presentation by @IreneBuvat @LitoCurie. Written coverage by @zklaassen_md @GACancerCenter > https://t.co/ZrGHzpDodX @PCFnews @PSMAconference #PSMAandBeyond2025 pic.twitter.com/k75BOmhDbQ
— UroToday.com (@urotoday) March 29, 2025
PCCTC Scientific Oversight Committee Chair @mjmorrismd.bsky.social discusses radioligand therapy strategies for polymetastatic castration-sensitive prostate cancer at the 2025 UCSF-UCLA PSMA Conference: www.urotoday.com/video-lectur...
— The PCCTC (@thepcctc.bsky.social) April 10, 2025 at 10:00 AM
[image or embed]
View all PSMA and Beyond 2025 Conference Videos via UroOnc.com
Written Conference Articles
Conference coverage included detailed analysis of the thirty-five publications associated with the presentations.
- CAR-T and Bispecific Antibodies Targeting PSMA
- Role of ADCs in Prostate Cancer
- Next Generation PSMA Radioligands
- PSMA-I&T vs PSMA-617: Is There a Difference?
- Role of PSMA Targeted Antibodies
- CA-IX in Renal Cell Cancer
- GRPR and Other Peptides for Targeting Prostate Cancer
- Keynote Lecture: Improving Outcomes with Combination Therapy
- Beyond PSMA in Prostate Cancer: STEAP1, DLL3, and CD46
- Role for Other Radionuclides: Tb161
- Opportunity for RLT in Bladder Cancer
- Overview of Clinical Trials of PSMA RLT in 2025
- How to Crush a PSMA PET Report: Guidelines and Scoring Systems
- Post-VISION: Real World Experience in the US, How Is PSMA RLT Being Used?
- Can We Kill the Bone Scan?
- Pre-chemo Trials: PSMAfore/SPLASH/ECLIPSE
- PRIMARY Score and Where it Plays a Role
- Can PSMA-Targeted Prostate Biopsy Detect Cancer When MRI-Guided Biopsy is Negative?
- PSMA RLT for Oligometastatic Disease
- Management of Dry Mouth
- PSMA RLT in a Radiation Oncology Private Center
- PSMA RLT in a Medical Oncology Private Center
- Ac225 PSMA Experience
- 212Pb-PSMA vs 225Ac-PSMA: from Biology to Supply
- Impact of Clinical Guidelines on the Utilization of PSMA PET
- Incorporating PSMA PET into Clinical Trials
- Landscape of Approved PSMA Imaging Agents: Does It Matter?
- Moving into the Castration Sensitive Setting
- Role of PSMA PET in Surgical Planning and Post-Operative Management
- PSMA-PET for Overall Survival Outcome Risk Stratification of Prostate Cancer
- Treatment Sequencing with Radioligand Therapy in mCRPC
- Whole Body PSMA Quantitative Parameters: Why Are We Not Using Whole Body PSMA PET Parameters in the Real World
- What’s the Best Way to Evaluate Response: SPECT vs PSMA PET?
- When Should We Use FDG PET?
- Who Benefits from Oligo-Metastases Directed Therapy?